Matt Huentelman
Matt Huentelman

Matt Huentelman Ph.D.

Professor
Neurogenomics Division

Scientific Director
Center for Rare Childhood Disorders

Head
Neurobehavioral Research Unit

Matt Huentelman Ph.D.

Dr. Huentelman's research interests center around the investigation of the “-omics” (genomics, transcriptomics, and proteomics) of neurological traits and disease. His laboratory’s overarching goal is to leverage findings in these disciplines to better understand, diagnose, and treat human diseases of the nervous system.

Dr. Huentelman joined TGen in July of 2004 after completing his doctoral work at the University of Florida’s Department of Physiology and Functional Genomics at the McKnight Brain Institute where he investigated the application of gene therapy in the study and prevention of hypertension. His undergraduate degree is in Biochemistry from Ohio University’s Department of Chemistry and Biochemistry at Clippinger Laboratories. His career includes visiting researcher stints in Moscow, Russia at the MV Lomonosov Moscow State University “Biology Faculty” and in the United Kingdom within the University of Bristol’s Department of Physiology. 

Alzheimer’s Disease | The Huentelman lab examines Alzheimer’s disease with the use of next generation DNA and RNA sequencing and cultured brain organoids. They are interested in helping to identify an individual’s personal risk for developing the disease as early as possible in life as well as identifying new drug targets and developing new drugs. They also undertake the genomic study of phenotypic outliers – like individuals who have extremely high risk for AD but who avoid the disease for their entire life – to better understand how Alzheimer’s progresses and may be prevented.

Aging | Like other physiological developmental stages, our individual response to the process of aging differs dramatically from person to person. Importantly the natural process of aging takes place over many decades and therefore our lifestyle choices, demographic factors, and medical conditions may play a major role in how each one of us ages. The Huentelman lab is using genomics and transcriptomics to better understand why some individuals exhibit better cognitive aging when compared to others. The hope is that through the better understanding of these differences they may someday be able to develop therapeutics that could enable a larger portion of the population to exhibit better cognitive aging. Conceptually they believe that this will require a true personalization of the approach to brain aging, something that they refer to as “Precision Aging”. Find out more at: precisionagingnetwork.org 

Cognition | Our individual differences in brain performance remain of great interest to the field of Neuroscience. Dr. Huentelman’s group leverages their innovative web-based approach to study the drivers of these individual differences in brain performance via their study site at  https://mindcrowd.org. The overarching goal of this research is to utilize this new information to improve brain performance in all humans with the hope of enabling greater number of individuals to avoid diseases of cognition or to decrease their severity. 

Rare Disease | The genetic dissection of rare human disease is uniquely powered by our ability to sequence the entire human genome and interpret the results with increasing clarity. The Huentelman laboratory utilizes this approach to tackle rare diseases in children - via TGen’s Center for Rare Childhood Disorders - as well as in adults. The greatest successes in this area come from the study of the entire nuclear family, therefore, Dr. Huentelman’s group typically focuses on the study of diseases that strike at a time in life when the affected patient and parent’s DNA can be studied together.

Mindcrowd Blog |  Be sure to check out the MindCrowd blog for the latest in healthy brain aging research. Go to https://blog.mindcrowd.org

 

Back To Top